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Abstract
Background: Herein we present the results of two related investigations. The first study determined if
concentrations in breast nipple discharge (ND) of two proteins (urinary plasminogen activator, uPA and its inhibitor,
PAI-1) predicted the presence of breast atypia and cancer in pre- and/or postmenopausal women requiring surgery
because of a suspicious breast lesion. The second study assessed if these proteins increased the predictive ability of
a carbohydrate (Thomsen Friedenreich, TF) which we previously demonstrated predicted the presence of disease in
postmenopausal women requiring surgery.
Methods: In the first study we prospectively enrolled 79 participants from whom we collected ND, measured uPA
and PAI-1 and correlated expression with pathologic findings. In the second study we analyzed 35 (uPA and PAI-1
in 24, uPA in an additional 11) ND samples collected from different participants requiring breast surgery, all of
whom also had TF results.
Results: uPA expression was higher in pre- and PAI-1 in postmenopausal women with 1) cancer (DCIS or invasive)
vs. either no cancer (atypia or benign pathology, p = .018 and .025, respectively), or benign pathology (p = .017
and .033, respectively); and 2) abnormal (atypia or cancer) versus benign pathology (p = .018 and .052,
respectively). High uPA and PAI-1 concentrations and age were independent predictors of disease in
premenopausal women, with an area under the curve (AUC) of 83-87% when comparing diseased vs. benign
pathology. uPA, TF, and age correctly classified 35 pre- and postmenopausal women as having disease or not 84-
91% of the time, whereas combining uPA+PAI-1+TF correctly classified 24 women 97-100% of the time.
Conclusions: uPA and PAI-1 concentrations in ND were higher in women with atypia and cancer compared to
women with benign disease. Combining uPA, PAI-1 and TF in the assessment of women requiring diagnostic
breast surgery maximized disease prediction. The assessment of these markers may prove useful in early breast
cancer detection.
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Background
Cancer cell invasion and metastasis requires the degra-
dation of the extracellular matrix (ECM) and basement
membrane. This process is accomplished by several pro-
teins, including those of the plasminogen activator (PA)
system. Urokinase-type PA (uPA) plays a key role in
ECM degradation. In women with breast cancer, uPA
appears to promote cancer invasion and metastasis [1]
through degradation of the ECM, stimulation of angio-
genesis, alteration in cell migration and adhesion [2],
and inhibition of apoptosis [3].
Plasminogen activator activity is inhibited by plasmi-
nogen activator inhibitor-1 (PAI-1) [4]. PAI-1 promotes
breast cancer invasion and metastasis. Deficient PAI-1
expression in mice prevented local invasion and tumor
vascularization of transplanted malignant keratinocytes.
When PAI-1 expression was restored, invasion and asso-
ciated angiogenesis were also restored, suggesting that
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any medium, provided the original work is properly cited.host-produced PAI-1 is essential for cancer cell invasion
and angiogenesis [5]. PAI-1 promotes angiogenesis by
directly inhibiting proteases [6], suggesting that exces-
sive plasmin proteolysis may prevent the assembly of
tumor blood vessels. Possib l em e c h a n i s m sb yw h i c h
PAI-1 promotes breast cancer include prevention of
excess ECM degradation, modulation of cell adhesion, a
role in angiogenesis, and the stimulation of cell prolif-
eration [1]. The association of uPA and PAI-1 expres-
sion with breast cancer is complex.
In a pooled analysis of 8377 breast cancer patients,
higher uPA and PAI-1 levels in tumor tissue were
related to worse prognosis [7]. The importance of the
PA system in breast cancer detection was explored by
us in a sample set ranging from healthy women to those
with advanced breast cancer, demonstrating that both
uPA and PAI-1 were useful in predicting which women
had breast cancer [8]. Specifically, high levels in breast
nipple aspirate fluid (NAF) of uPA and PAI-1 signifi-
cantly contributed to a model which predicted which
women had breast cancer. In that study, we observed
that uPA and PAI-1 are concentrated in NAF (a type of
nipple discharge-ND, in addition to spontaneous ND,
which can be physiologic or pathologic) compared to
plasma [8]. Pathologic spontaneous ND (PND) comes
forth from one but not the other breast nipple and gen-
erally the breast with PND harbors a benign or malig-
nant tumor [9]. On the other hand, physiologic
spontaneous ND is generally from both breasts and is
not associated with cancer. Both NAF and PND can be
obtained non-invasively and contain concentrated
secreted proteins, carbohydrates and lipids from the
breast ductal epithelium, the cells that give rise to can-
cer. This fact, as well as the fact that ND is breast speci-
fic, undiluted by the contribution from other organs,
suggests that it may be a better physiologic fluid than
plasma to identify breast cancer biomarkers.
In this study we demonstrate in a specific population
of participants (women with a suspicious breast lesion
which required biopsy to exclude cancer) that the
expression of uPA and PAI-1 is altered in women with
breast atypia and cancer. Since these markers were
more predictive of disease in pre- than in post-meno-
pausal women, and were not perfectly accurate in pre-
dicting the presence of disease in either menopausal
group, we wondered if additional marker(s), ideally one
or more that was especially predictive of postmenopau-
sal disease, would improve the ability of uPA and PAI-1
to predict the presence of breast atypia or cancer.
We previously reported [9] that the Thomsen-Frieden-
reich (TF; Galactose-b-(1 ® 3)-N-acetyl-D-galactosa-
mine) antigen, which is displayed on cell-surface
proteins and lipids in 70% to 90% of adenocarcinomas
of the breast [10], is upregulated in post- (but not pre-
menopausal) women with breast atypia and cancer, cor-
rectly classifying either cancer or abnormal vs. benign
pathology 83% of the time in postmenopausal women.
Because uPA and PAI-1 was also predictive in postme-
nopausal women, we hoped that it might increase the
predictive ability of TF in these women. Because uPA
was more predictive in premenopausal women, we
hoped that it would increase the predictive ability in this
group. We therefore evaluated all three markers in a
matched subset of the 124 samples in which TF analysis
was reported [9] and sufficient ND remained.
Methods
Patients and samples
After receiving Institutional Review Board approval, we
obtained informed consent, prospectively enrolled parti-
cipants and collected 79 ND samples in Grand Forks,
North Dakota, at the University of North Dakota, in
Columbia, MO, at the Ellis Fischel Cancer Center and
in London, UK, at the Royal Marsden Cancer Center.
Participants were enrolled from January 2008 to Febru-
ary 2010. Details of TF sample collection and analysis
were previously reported [9]. Among the 124 ND sam-
ples collected in the TF report there was sufficient
remaining NAF to analyze both uPA and PAI-1 in 24
and uPA alone in an additional 11 samples. Criteria for
enrollment were the same in the current as in the TF
report. A subject was classified as postmenopausal if at
least one year had passed without a menstrual period or
she had undergone bilateral oophorectomy prior to
enrollment. Women who had undergone hysterectomy
without bilateral oophorectomy were considered post-
menopausal if they were over 50 years old. If follicle sti-
mulating hormone (FSH) levels were available, a level of
34 mIU/mL or greater was used to classify women as
postmenopausal. All ND samples were collected prior to
excisional biopsy or mastectomy. Comparisons of uPA,
PAI-1 and TF were based on the histopathologic find-
ings in the clinical report. For the purposes of this
report, we define “cancer” as pathologic evidence of
either ductal carcinoma in situ (DCIS) or invasive can-
cer; “no cancer” as histopathology which was normal,
usual hyperplasia, and/or atypical hyperplasia; “benign”
as histopathology containing normal findings and/or
usual hyperplasia; and “abnormal” as histopatology
demonstrating atypical hyperplasia, DCIS, and/or inva-
sive cancer.
Sample collection
ND (1-10 μL )w a so b t a i n e df r o mt h eb r e a s tw i t ha
lesion prior to surgery. Lesions included women with 1)
pathologic nipple discharge (PND); 2) a suspicious
lesion identified on imaging, be it mammogram, ultra-
sound or breast magnetic resonance imaging; and/or 3)
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were collected as described previously [11]. Briefly, after
informed consent was obtained, ND fluid was aspirated
using a breast pump (NAF) or collected after the partici-
pant massaged her breast (PND). Samples were collected
into capillary tubes, the volume of NAF measured and
stored at -80°C until use.
Preparation
The portion of the capillary tube containing the sample
was introduced into a 1.7 mL Eppendorf tube and
100 μL of a 0.1 mol/L solution of sodium bicarbonate
(pH 7.8) added. The capillary tube was then crushed
with a glass rod and the mixture vortexed to disperse
the sample. The crushed capillary tube was left in the
bicarbonate buffer overnight at 4°C, and the mixture
then centrifuged (14,000 g, 5 min) and the supernatant
used without further dilution.
Analysis
uPA and PAI-1. ELISA kits for uPA and PAI-1 were
obtained from American Diagnostica, Inc. (Greenwich,
CT). Levels of these two markers in ND samples were
determined according to the manufacturer’s instructions.
Briefly, 100 uL of standards, samples and blanks were
pipetted into microplate wells coated with monoclonal
antibodies respectively specific for uPA and PAI-1 and
incubated overnight at 4°C. After washing (× 4),
enzyme-linked antibodies specific for each analyte were
added to the wells and incubated for 1 h at room tem-
perature. The wells were washed again, diluted enzyme
conjugate (streptavidin conjugated horseradish peroxi-
dase) was pipetted into the wells, incubated (1 h, RT),
then washed again. Substrate reagent was added to each
well, followed by a stop solution (0.5 M sulfuric acid).
Absorbance was measured with a microplate reader.
Detection limits were 10 pg/mL for uPA and 50 pg/mL
for PAI-1.
TF. The evaluation of this carbohydrate was previously
reported [9].
Statistical analysis
Biomarker levels for uPA and PAI-1 in the ND samples
were heavily skewed and not normally distributed. We
therefore described and analyzed biomarker levels using
medians and log-transformed (Log10) means to achieve
normal distributions. We performed a Shapiro-Wilk test
to determine the goodness-of-fit of the data to a normal
distribution. None of the log-transformed variables were
significantly different from a normal distribution.
Unpaired t-tests were calculated to determine significant
differences between log10 means of the biomarkers.
Logistic regression analyses are based on log10 trans-
formed data. Three logistic regression models were used
to examine the effects of uPA and PAI-1 in predicting
(a) cancer vs. no cancer diagnosis; (b) cancer vs. benign
diagnosis; and (c) abnormal vs. benign diagnosis. Var-
ious demographic factors, include age, menopausal sta-
tus, and hormone replacement, were included in the
logistic models as covariates. Because menopausal status
was a near significant predictor in all three overall logis-
tic models, follow-up logistic models were conducted
separately for pre- and for post-menopausal women,
controlling for age. Receiver operating characteristic
(ROC) curves were calculated based on the logistic
regression results for the premenopausal women’s data,
and area under the curve (AUC) values are presented.
The optimal subset of all variants, uPA, PAI-1, TF, Tn,
and covariates was selected to achieve the best AUC
value.
Results
Recruitment
NAF was successfully collected in 90% (76/84) and PND
in 100% (3/3) women. Among the 79 women evaluated
for uPA and PAI-1 expression, 41 (51.9%) were postme-
nopausal. Age ranged from 21 to 82 years, with a med-
ian age in pre- and postmenopausal women of 44 and
61, respectively. Among the 35 women evaluated for TF,
uPA +/- PAI-1 expression, 17 (48.6%) were postmeno-
pausal. Age ranged from 26 to 77 years, with a median
age in pre- and postmenopausal women of 43.5 and 61
years, respectively.
Fluid volume and biomarker expression not different
among women with vs. those without PND
ND volume ranged from 4 to 521 μl, with a mean of
60.9 and median of 29 μl. ND volume did not vary by
pathologic diagnosis nor by fluid type (NAF vs. PND).
We first determined if uPA and PAI-1 expression in
women requiring diagnostic biopsy due to PND differed
from expression in women requiring biopsy who did not
have PND. Results of logistic regression analyses con-
ducted using samples from women with PND and NAF
showed that fluid type did not affect expression levels,
with p > 0.5 for all biomarkers. Therefore, all reported
analyses include both PND and NAF samples (N = 79).
uPA concentration is associated with breast atypia and
cancer
uPA concentration was higher (Table 1) in women with
cancer (DCIS or invasive) than in women with 1) no
cancer: atypia or benign pathology (p = .023), and 2)
benign pathology (p = .025). uPA was also higher in
women with abnormal (atypia or cancer) than benign
pathology (p = .050). PAI-1 was higher in women with
cancer (DCIS or invasive) than in women with benign
pathology (p = .037).
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Univariate analysis indicated that uPA concentration
was more predictive of disease in premenopausal
women, and PAI-1 in postmenopausal women (Table 1).
uPA concentration was higher in premenopausal women
with cancer (DCIS or invasive) than in women with 1)
no cancer (p = .018), and 2) benign pathology (p =
.017), and in women with abnormal pathology than
those with benign pathology (p = .018). PAI-1
concentration was higher in postmenopausal women
with cancer (DCIS or invasive) than in women with 1)
no cancer (p = .025), and 2) benign pathology (p =
.033).
In 79 ND samples, we generated ROC curves to deter-
mine how well information on uPA and age predicted if
a premenopausal woman had breast atypia or cancer.
Three comparisons: cancer vs. no cancer, cancer vs.
benign pathology, and abnormal vs. benign pathology
were conducted. The AUC values ranged from .83-.87
(Table 2), and were better than those for postmenopau-
sal women.
The combination of TF, uPA and PAI-1 are highly
predictive of the presence of breast cancer
Among the 79 samples evaluated for uPA+PAI-1
expression, the AUC for age alone was .62. The AUC
for uPA, PAI-1 and age ranged from .72 to .75 when
predicting disease in all women, whereas the AUC for
uPA and age in premenopausal women only was higher
(.83-.87). We then measured uPA and PAI-1 in NAF
collected contemporaneously with that used to measure
TF. For all of these analyses, age was in the predictive
model. TF+uPA predicted disease in both pre- and post-
menopausal women with 84-92% accuracy. When TF,
uPA, and PAI-1 were combined, the predictive ability
approached 100% (Table 2, Figure 1).
Discussion
Carbohydrate biomarkers have not been investigated as
extensively as proteins in NAF or other bodily fluids.
Nonetheless, there have been studies dating back to at
least 1989 in which the carbohydrate lactose was mea-
sured in [12]. Lactose, whose presence was felt to indi-
cate evidence of breast secretory activity, was detected
Table 1 Univariate analyses of uPA and PAI-1 expression
(ng/mL) in women requiring breast surgery
A. Cancer/no cancer Overall No cancer
1 Cancer
1 P value
All Subjects (N) 79 46 33
uPA Mean (SD) 2.4 (.90) 2.2 (.84) 2.7 (.92) .023
Median 2.4 2.2 2.6
PAI-1 Mean (SD) 3.7 (1.5) 3.4 (1.4) 4.2 (1.6) .064
Median 3.5 3.3 4.1
Premenopausal (N) 38 23 15
uPA Mean (SD) 2.5 (.93) 2.2 (.82) 2.9 (.93) .018
Median 2.5 2.3 2.7
Postmenopausal (N) 41 23 18
PAI-1 Mean (SD) 4.0 (1.6) 3.5 (1.6) 4.6 (1.4) .025
Median 3.8 3.3 4.3
B. Cancer/benign Overall Benign
1 Cancer
1 P value
All Subjects (N) 72 39 33
uPA Mean (SD) 2.4 (.93) 2.2 (.89) 2.7 (.92) .025
Median 2.4 2.2 2.6
PAI-1 Mean (SD) 3.7 (1.5) 3.4 (1.4) 4.2 (1.6) .037
Median 3.4 3.1 4.1
Premenopausal (N) 37 22 15
uPA Mean (SD) 2.4 (.95) 2.2 (.84) 2.9 (.93) .017
Median 2.5 2.2 2.7
Postmenopausal (N) 35 17 18
PAI-1 Mean (SD) 4.0 (1.7) 3.4 (1.7) 4.6 (1.4) .033
Median 3.8 2.8 4.3
C. Abnormal/benign Overall Benign
1 Abnormal
1 P value
All Subjects (N) 79 39 40
uPA Mean (SD) 2.4 (.90) 2.2 (.89) 2.6 (.88) .050
Median 2.4 2.2 2.5
PAI-1 Mean (SD) 3.7 (1.5) 3.4 (1.4) 4.0 (1.6) .060
Median 3.5 3.1 3.9
Premenopausal (N) 38 22 16
uPA Mean (SD) 2.5 (.93) 2.2 (.84) 2.9 (.91) .018
Median 2.5 2.2 2.7
Postmenopausal (N) 41 17 24
PAI-1 Mean (SD) 4.0 (1.6) 3.4 (1.7) 4.4 (1.3) .052
Median 3.8 2.8 4.1
1No cancer = normal, hyperplasia, and atypical hyperplasia; Cancer = ductal
carcinoma in situ and invasive cancer; Benign = normal and hyperplasia;
Abnormal = atypical hyperplasia, ductal carcinoma in situ and invasive cancer.
Means and medians reflect log10 values for each marker. For all subjects, all p
values are provided regardless of the result. For pre- and postmenopausal
groupings, only results which were significant or approached significance (p <
.065) were included
Table 2 AUC values for disease prediction considering
uPA, PAI-1, TF and age
1
Biomarker Group N
1 AUC
CA/no
CA
2
CA/
benign
2
Abnormal/
benign
2
uPA+PAI-1 All 79 .72 .75 .74
uPA
3 Pre 38 .87 .83 .86
TF
4 Post 72 .81 .83 .83
TF+uPA All 35 .84 .92 .91
TF+uPA+PAI-
1
All 24 1.0 1.0 .97
1AUC: area under the receiver operating curve; uPA: urinary plasminogen
activator; PAI (uPA inhibitor)-1, TF: Thomsen-Friedenreich antigen; N = number
or sample size. The equivalent values as percent should be multiplied by 100
(i.e., .97 = 97%, and so forth)
2Cancer = ductal carcinoma in situ (DCIS), and invasive cancer; Benign =
normal and hyperplasia; Abnormal = atypical hyperplasia, DCIS, and invasive
cancer. Age is in all three models
3AUC values for postmenopausal women were lower
4previously published data [9]
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detected in 100% of samples from women less than age
30 to being detected in 29% of samples from women ≥
35 years old. A more recent study demonstrated that
dietary intake of lactose was a strong predictor of the
ability to collect NAF [13]. The measurement of TF
antigen in NAF from 23 women with biopsy proven
breast cancer using the galactose oxidase-Schiff (GOS)
reaction was reported in 2004 [14]. The change in color
with the reaction was significantly different between
NAF from cancer containing vs. NAF from healthy con-
tralateral breasts. We reported [9] levels of TF measured
by direct immunoassay in 124 ND samples, including 52
from pre- and 72 from post-menopausal women with a
suspicious breast lesion which required biopsy. Age
alone in this cohort provided an AUC of .69. TF and
age predicted the presence of atypia and cancer in the
postmenopausal group with an AUC of .83. In an analy-
sis of 79 ND samples (different than the 124) with simi-
lar enrollment criteria, uPA was highly predictive of
breast cancer in premenopausal women (.83-.87), but
less so in postmenopausal women. We then determined
that two markers were better than one in predicting dis-
ease in all women, with TF + uPA having an AUC of
.84-.92. When TF, uPA, and PAI-1 were combined, the
AUC approached 1.0%.
We previously found that the expression of some ND
cancer prediction markers varied based on whether or
not the subject requiring surgery did or did not have
PND [15]. On the other hand, TF concentration was not
influenced by the presence or absence of PND [9]. We
therefore determined if uPA and PAI-1 concentrations
differed based on whether the sample was PND or NAF.
Since we did not identify a concentration difference, all
analyses included both PND and NAF samples.
We have three NAF biomarkers (TF, uPA and PAI-1)
which together appear highly predictive of the presence
of cancer or precancer in women requiring breast biopsy
to exclude disease. The markers appear to be highly pre-
dictive of disease, regardless of whether or not PND was
present. The NAF markers appear complementary, as
two of the biomarkers (TF and PAI-1) are more predic-
tive in post- than premenopausal women, whereas uPA
is more predictive in premenopausal women.
Figure 1 ROC curves for the prediction of breast cancer. TF, uPA, PAI-1 and age information were used to generate curves comparing
cancer = DCIS and invasive cancer vs. no cancer = normal, hyperplasia and atypical hyperplasia: TF and age in postmenopausal women (AUC =
.81) (A), uPA and age in premenopausal women (AUC = .87) (B); TF, uPA and age in all (pre- and postmenopausal) women (AUC = .84) (C); and
TF, uPA, PAI-1 and age in all women (AUC = 1.0) (D). AUC for each illustration is indicated by blue shading.
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s t u d yw a st h es m a l ls a m p l es i z ef o rt h ea n a l y s i so fa l l
three markers. Second, TF was analyzed at a different
time than uPA and PAI-1. How much the age of the
samples influenced marker expression is uncertain,
though we did determine that uPA and PAI-1 expres-
sion was similar between the groups of 79 and 24 sam-
ples. A validation study in a larger sample size would
help to determine the predictive ability of uPA, PAI-1
and TF would help to address these limitations.
Conclusions
In women requiring breast biopsy to exclude disease,
combining ND biomarkers that were each predictive of
the presence of atypia or cancer improved the prediction
of both atypia and cancer, regardless of whether or not
PND was present. A validation study is warranted to
determine the clinical use of these noninvasive markers.
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